Using Overseas Evidence for ARTG Medical Device Applications
What the TGA Accepts (and What It Doesn’t)
Global medical device manufacturers increasingly approach Australia with confidence. Many arrive with European CE marking or United States Food and Drug Administration (FDA) clearance already secured. On the surface, this creates a perception that entry to the Australian market should be straightforward. In practice, however, the Therapeutic Goods Administration (TGA) maintains distinct regulatory expectations that can challenge even experienced sponsors.
Australia’s regulatory framework actively encourages the use of overseas evidence. The TGA recognises conformity assessment outcomes from comparable regulators and has built formal reliance pathways into its legislation. This approach can reduce duplication, shorten timelines, and support faster access to the Australian Register of Therapeutic Goods (ARTG). Yet the system is not designed as a simple “passport” for foreign approvals. The TGA still requires clear evidence that Australian legislative requirements are met.
The risk arises when sponsors assume equivalence without checking alignment. CE marking or FDA clearance may demonstrate a strong baseline. However, differences in classification, Essential Principles, post-market obligations, and documentation structure frequently lead to gaps. These gaps appear during application audits, requests for information, or post-market reviews, which may delay approval or increase regulatory risk.
This blog explores how overseas regulatory evidence fits into the ARTG process, where it adds value, and where it falls short. It also provides practical guidance to help sponsors bridge the gap between international approvals and Australian expectations.
Overview of TGA reliance on overseas regulators
The TGA has progressively strengthened its reliance framework over the past decade. Sponsors can now leverage assessments performed by recognised overseas regulators as part of their Australian regulatory strategy. These include European notified bodies, the US FDA, Health Canada, Japan’s PMDA, Singapore’s HSA, UK approved bodies, and Medical Device Single Audit Program (MDSAP) Auditing Organisations.
At the centre of this approach is Manufacturer’s Evidence (ME). This evidence demonstrates that an appropriate conformity assessment has been applied to the device. In many ARTG applications, overseas certificates provide the foundation for this evidence, reducing the need for a full TGA conformity assessment.
In practice, Sponsors should treat overseas evidence as supporting evidence rather than a substitute for Australian compliance. Sponsors still need to show that the device, intended purpose, labelling, post-market arrangements, and Essential Principles evidence align with Australian regulatory requirements.
The extent of reliance also depends on device classification and risk. Higher-risk devices may face application audits or additional scrutiny. Even when overseas evidence is accepted, the TGA can request supplementary documentation or conduct targeted assessments.
A Class IIb device with EU MDR certification may achieve ARTG inclusion using notified body certification as Manufacturer’s Evidence. However, if the clinical evaluation lacks justification for the Australian intended use population, the TGA may request additional data before approval.
When CE certificates can be leveraged, and when they can’t
TGA data has historically identified European notified body certification as a dominant source of Manufacturer’s Evidence for Australian medical device applications. Sponsors should still confirm that the certificate type, scope, device classification, and intended purpose support the proposed ARTG inclusion.
The TGA recognises CE certificates issued under the Medical Device Regulation (EU MDR) or, in some transitional cases, legacy directives. These certificates can support Manufacturer’s Evidence and may allow sponsors to follow an abridged pathway rather than undergoing a full TGA conformity assessment.
Despite this alignment, key limitations remain.
First, compliance with European requirements does not guarantee compliance with Australian legislation. The TGA explicitly maintains separate regulatory requirements and may audit applications to confirm that local obligations are met.
Second, classification differences can affect the validity of CE-based strategies. Although classification systems are broadly aligned, exceptions may exist. Sponsors should classify the device under the Australian medical device rules rather than relying on the overseas classification outcome. Even where the overseas and Australian classifications appear similar, the Australian classification determines the ARTG pathway, supporting documents, and whether the application is likely to be selected or required for audit.
Third, certain device categories historically required TGA-issued conformity assessment. While reforms have expanded acceptance of CE evidence, the TGA still retains discretion to conduct detailed reviews, particularly for higher-risk products.
A manufacturer holds an MDR CE certificate for an implantable device. When submitting to the ARTG, the TGA requests further evidence on material safety specific to Australian clinical expectations, as the notified body report does not fully address these parameters.
FDA clearance vs TGA expectations
FDA clearance or approval provides valuable regulatory evidence but operates under a different framework from the TGA. For example, the FDA’s 510(k) pathway focuses on demonstrating substantial equivalence to a predicate device. In contrast, the TGA requires demonstration of compliance with Essential Principles covering safety, performance, and lifecycle management.
The TGA has expanded its acceptance of FDA evidence in recent years. Sponsors can now use FDA approvals, including 510(k) clearances in certain circumstances, to support ARTG applications. However, these applications often require additional elements such as a Medical Device Single Audit Program (MDSAP) quality management system certificate.
Another key difference lies in regulatory scrutiny. Where FDA clearance may rely on equivalence, the TGA may require more explicit alignment with the Essential Principles. This includes demonstrating that benefits outweigh risks, supported by clinical and post-market evidence.
Depending on the device class, evidence pathway and applicable audit criteria, ARTG applications that rely on FDA evidence may be selected or required for application audit.
A Class III device with FDA 510(k) clearance is submitted for ARTG inclusion. The TGA initiates an audit and requests additional clinical justification, as the predicate-based rationale does not fully address Australian safety expectations.
Practical guidance: Aligning overseas technical files to Australian requirements
Bridging the gap between overseas approvals and TGA expectations requires structured preparation. Sponsors should treat overseas evidence as a starting point rather than a complete submission.
1. Map to Essential Principles early
The Essential Principles define safety and performance requirements for all devices supplied in Australia. Manufacturers must demonstrate compliance with these principles using objective evidence, including design documentation, testing, and clinical evaluation.
A structured gap analysis should map existing technical documentation against each relevant principle. This ensures that evidence developed for other jurisdictions remains valid in the Australian context.
2. Confirm classification and pathway
Classification drives the regulatory pathway, level of scrutiny, and documentation requirements. Even small differences between EU and Australian classification rules might alter the submission strategy or trigger audits.
Sponsors should confirm classification under Australian rules rather than assuming alignment with EU or US systems.
3. Localise documentation and labelling
The TGA focuses on Australia-specific requirements, including labelling, instructions for use, and sponsor obligations. Overseas documentation should be reviewed and updated to reflect these expectations.
4. Strengthen clinical and risk evidence
The TGA emphasises documented risk management and clinical evidence demonstrating that benefits outweigh risks. This may require augmenting overseas clinical evaluations with additional justification or post-market data.
5. Prepare for audit scenarios
Sponsors should assume that higher-risk devices or reliance-based applications may be audited. Preparing concise, traceable documentation improves audit readiness and reduces response time.
6. Establish governance and ownership
Assign clear ownership for regulatory compliance across global and local teams. Ensure that the Australian sponsor has access to complete technical documentation and can respond to TGA requests promptly.
Checklist: Using overseas evidence for ARTG submission
- Confirm device classification under Australian rules
- Identify applicable reliance pathway
- Validate Manufacturer’s Evidence scope
- Map technical file to Essential Principles
- Localise labelling and instructions for use
- Verify QMS certification (e.g. MDSAP where required)
- Review clinical evidence for Australian applicability
- Prepare audit-ready documentation
- Establish sponsor responsibilities and access to data
- Plan for post-market surveillance and reporting
Checklist: Signs your documentation needs rework
- Gaps in Essential Principles mapping
- Inconsistent intended use statements across regions
- Limited traceability between risk management and clinical evidence
- Missing Australian-specific labelling elements
- Outdated or incomplete QMS certificates
- Lack of post-market surveillance strategy
- Over-reliance on equivalence without justification
- Fragmented or poorly organised technical documentation
Potential pitfalls
- Assuming CE marking guarantees ARTG inclusion without additional evidence
- Submitting overseas documentation without mapping to Essential Principles
- Misalignment between EU/FDA intended use and Australian claims
- Incorrect device classification under Australian rules
- Missing or outdated Manufacturer’s Evidence
- Over-reliance on FDA equivalence without clinical justification
- Incomplete or inconsistent labelling for Australian requirements
- Weak link between risk management and clinical evaluation
- Failure to prepare for TGA application audits
- Poor document control and traceability within technical files
- Lack of clarity on sponsor responsibilities and obligations
- Inadequate planning for post-market surveillance in Australia
Conclusion: Actions for sponsors
The TGA’s reliance framework provides a valuable opportunity for sponsors to leverage global regulatory investments. CE marking and FDA clearance can significantly streamline the path to ARTG inclusion when used correctly. However, these approvals do not replace the need to meet Australian regulatory requirements in full.
Successful submissions recognise this distinction early. They treat overseas evidence as a foundation, not a finished dossier. Sponsors can reduce delays and improve regulatory outcomes by aligning technical documentation with the Essential Principles, confirming classification, and preparing for audit scenarios.
Key actions for sponsors:
- Conduct an early gap assessment against Australian requirements
- Confirm classification and regulatory pathway before submission
- Align technical files to Essential Principles
- Strengthen clinical and risk evidence where needed
- Prepare for potential TGA audits
- Ensure clear governance between manufacturer and sponsor
A deliberate and structured approach transforms overseas evidence from a risk into a strategic advantage.
PharmOut Services & Training
PharmOut consultants can support medical device applicants with ARTG strategy, overseas evidence gap assessments, Essential Principles mapping, technical file review, audit preparation, sponsor obligations and tailored training. Our team helps translate global regulatory evidence into practical, submission-ready documentation for the Australian market.
Explore elearning and public courses via onlinegmptraining.com, or contact us via the website or via email to tailor workshops to your needs.
Frequently Asked Questions (FAQ)
Yes. CE marking can often support an ARTG application when the certificate is current, relevant and within scope. Sponsors still need to confirm Australian classification, Manufacturer’s Evidence, labelling and Essential Principles compliance before relying on it.
No. FDA 510(k) clearance may support an ARTG application, but it does not automatically qualify a device for inclusion. The TGA may require additional evidence, including Essential Principles mapping, clinical justification and, in some cases, MDSAP certification.
Manufacturer’s Evidence is the conformity assessment evidence that shows the manufacturer has applied appropriate procedures for the device. It supports ARTG inclusion and may include TGA certification, recognised overseas evidence or other accepted conformity assessment documentation.
Mapping overseas evidence to the Essential Principles helps demonstrate that the device meets Australian safety and performance requirements. It also highlights gaps between overseas technical files and local expectations before the TGA raises questions or requests further information.
The TGA may audit applications for higher-risk devices, certain device categories or submissions relying on overseas evidence. Audits check whether the application, evidence, classification, intended purpose and supporting documentation adequately meet Australian regulatory requirements.
Not usually without review. Overseas labelling should be checked against Australian requirements, including intended purpose, sponsor details, instructions for use and any required warnings. Minor updates may be needed to ensure local compliance and consistency.
